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Abstract
Purpose
188Re-HEDP is indicated for the treatment of pain
in patients with painful osteoblastic bone metastases,
including hormone-refractory prostate cancer patients.
Efficacy may be improved by adding chemotherapy to the
treatment regimen as a radiation sensitizer. The combina-
tion of
188Re-HEDP and capecitabine (Xeloda®) was tested
in a clinical phase I study.
Methods Patients with hormone-refractory prostate cancer
were treated with capecitabine for 14 days (oral twice daily
in a dose escalation regimen with steps of 1/3 of 2,500 mg/
m
2 per day in cohorts of three to six patients, depending on
toxicity). Two days later patients were treated with
37 MBq/kg
188Re-HEDP as an intravenous injection. Six
hours after treatment post-therapy scintigraphy was per-
formed. Urine was collected for 8 h post-injection. Follow-
up was at least 8 weeks. The primary end-point was to
establish the maximum tolerable dose (MTD) of capecitabine
when combined with
188Re-HEDP. Secondary end-points
included the effect of capecitabine on the biodistribution and
pharmacokinetics of
188Re-HEDP.
Results Three patients were treated in the first and second
cohorts, each without unacceptable toxicity. One of six
patients in the highest cohort experienced unacceptable
toxicity (grade 4 thrombopaenia). The MTD proved to be
the maximum dose of 2,500 mg/m
2 per day capecitabine.
No unexpected toxicity occurred. Capecitabine had no
effect on uptake or excretion of
188Re-HEDP.
Conclusion Capecitabine may be safely used in combina-
tion with
188Re-HEDP in a dose of 2,500 mg/m
2 per day
and 37 MBq/kg, respectively. Efficacy will be further
studied in a phase II study using these dosages.
Keywords Bonemetastases.PhaseI.Rhenium.
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Introduction
The majority of patients with hormone-refractory prostate
cancer have, or will have, osseous metastases in the course
of their disease [1]. Treatment with bone-seeking radio-
pharmaceuticals may be indicated when they experience
refractory bone pain at multiple sites. Bone-seeking radio-
pharmaceuticals decrease pain and improve the patients’
quality of life [2]. This effect may be increased by
concomitant use of chemotherapy, used as a radiation
sensitizer. Some studies show promising results on the use
of chemotherapy as a radiation sensitizer for bone-seeking
radiopharmaceuticals, but evidence is still low [3–5].
However, it is clear that multimodality treatment may
enhance efficacy and may lead us beyond palliation alone
towards improvement of survival [6]. In the present study
the combination of the bone-seeking radiopharmaceutical
188Re-HEDP and capecitabine chemotherapy was studied in
a phase I setting.
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e-mail: M.Lam@umcutrecht.nl188Re-hydroxyethylidene-1,1-diphosphonic acid (
188Re-
HEDP) is a relatively new and attractive radiopharmaceutical
for the treatment of metastatic bone pain. It has an affinity
for skeletal tissue and concentrates in areas of bone turnover
secondary to invasion by tumour. As a product of a
188W/
188Re generator, it is convenient for clinical therapeutic
use, because of on demand use at relatively low costs. The
radioisotope, with a half-life of 16.9 h, emits a 155 keV
gamma ray (15%) for external imaging and a number of beta
particles (Eb max2:12 MeV; Eb mean0:76 MeV) for localized
radiotherapy [7, 8]. Therapy with
188Re-HEDP results in
symptomatic relief of bone pain in approximately 70–80% of
treated patients.
188Re-HEDP is an effective and well-
tolerated treatment in the management of metastatic bone
pain [9–12].
Capecitabine is a fluoropyrimidine carbamate with
antineoplastic activity. It is an orally administered sys-
temic prodrug of 5′-deoxy-5-fluorouridine which is con-
verted to 5-fluorouracil (5-FU) inside the tumour cell by
thymidine phosphorylase. 5-FU is metabolized to 5-
fluoro-2′-deoxyuridine monophosphate (FdUMP) and 5-
fluorouridine triphosphate (FUTP). These metabolites
cause cell injury by two different mechanisms. First,
FdUMP and the folate cofactor, N-5-10-methylenetetrahy-
drofolate, bind to thymidylate synthase to form a cova-
lently bound ternary complex. This binding inhibits the
formation of thymidylate from 2′-deoxyuridylate. Thymi-
dylate is the necessary precursor of thymidine triphos-
phate, which is essential for the synthesis of DNA, so that
a deficiency of this compound can inhibit cell division.
Second, nuclear transcriptional enzymes can mistakenly
incorporate FUTP in place of uridine triphosphate during
the synthesis of RNA. This metabolic error can interfere
with RNA processing and protein synthesis [13, 14].
5-FU has long been used as a radiation sensitizer. Within
a few years of the discovery of 5-FU, radiation sensitization
by 5-FU was used in clinical trials. Improved survival and
local control with acceptable toxicity profiles were shown
in cancers of the oesophagus, anus and rectum [15, 16]. 5-
FU chemoradiation schedules were optimized and oral 5-
FU analogues that may be substituted for intravenous
administration were developed. The sensitizing effects of
5-FU in vitro are maximal when exposure to 5-FU occurs
for at least 24 h and up to 48 h after the radiation exposure,
supporting the use of continuous infusion or oral 5-FU
analogues instead of bolus intravenous administration [17].
Capecitabine (Xeloda®) can be administered orally, result-
ing in continuous high levels of active FU. In contrast to 5-
FU, capecitabine has an improved therapeutic to toxicity
index, because it is metabolized to cytotoxic 5-FU in the
target cell by way of thymidine phosphorylase. Measuring
the activity of thymidine phosphorylase in normal and
cancerous prostatic tissue has shown significantly higher
levels in cancerous tissue, making capecitabine a potential-
ly more active agent against prostate cancer than 5-FU [18,
19]. Compared to oral 5-FU prodrugs, protracted venous
infusion is costly, inconvenient and has a risk of central line
maintenance. Capecitabine is currently used as a radiation
sensitizer in several cancer types, like advanced colorectal
cancer and pancreatic cancer [16, 20].
Radiation sensitization by capecitabine in hormone-
refractory prostate cancer patients has never been described.
Like in other cancer types, it could lead to enhancement of
the radiation effect in prostate cancer [14]. This radiation-
sensitizing effect of capecitabine could enhance the
palliative effect of treatment with the bone-seeking radio-
pharmaceutical
188Re-HEDP. The primary aim of this phase
I study was to establish the safety and toxicity profile and to
determine the maximum tolerated dose (MTD) of capeci-
tabine combined with
188Re-HEDP. Secondary end-points
included the effect of capecitabine on the biodistribution
and pharmacokinetics of
188Re-HEDP.
Materials and methods
Study population
Patients with histologically documented adenocarcinoma of
the prostate, progressive hormone-refractory disease and
more than one painful bone metastasis (
99mTc-HDP scintig-
raphy within 8 weeks prior to screening) were included in
this open-label prospective phase I study. Other inclusion
criteria were a Karnofsky performance score of at least 60%,
life expectancy of at least 3 months, age of at least 18 years
and the ability to understand and willingness to sign an
informed consent document. Patients receiving bisphospho-
nate therapy had to discontinue their treatment for at least
2 weeks prior to study entry, and patients under luteinizing
hormone-releasing hormone (LH-RH) agonists (and/or anti-
androgens) had to continue their treatment. Patients with
pathological long-bone fractures or clinically evident spinal
cord compression and patients with known malignancies
other than prostate cancer (not including basal cell carcinoma
of the skin) were excluded. Other exclusion criteria were
chemotherapy (including Estracyt®) within 6 weeks prior to
screening; prior treatment with systemic radiotherapeutic
bone agents within 3 months (6 months for
89Sr); receipt of
any other investigational drug within 4 weeks of study entry;
previous hemi-body external radiation therapy (for >25% of
the bone marrow within 6 months); concomitant treatment
with interferon-alfa, allopurinol, sorivudine and folinic acid;
clinically significant bleeding disorders; disseminated intra-
vascular coagulation; hypersensitivity to phosphonate com-
pounds or 5-FU; known deficiency of dihydropyrimidine
dehydrogenase; concurrent illnesses or treatments that might
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metastasis; absolute neutrophil count (ANC) < 2×10
9/l;
platelet count < 150×10
9/l; haemoglobin < 6.0 mmol/l;
serum creatinine clearance < 50 ml/min (Cockroft and
Gault); bilirubin > 1.5 upper limit of normal; aspartate
aminotransferase (AST)/alanine aminotransferase (ALT) >
2.5 upper limit of normal; or total prostate-specific antigen
(PSA) < 5 ng/ml. The study was approved by the local
Ethics Committee, and written informed consent was
obtained from all patients.
188Re-HEDP
188Re was obtained from an alumina-based
188W/
188Re-
generator on site. The
188W was produced by double-
neutron capture of
186 W. Elution of the
188W/
188Re-generator
with 3 ml normal saline provided solutions of carrier-free
188Re sodium perrhenate (NaReO4). High-performance liquid
chromatographic (HPLC) analysis revealed that the
188Re
eluate was > 99% perrhenate [7].
188W/
188Re-generators have
demonstrated consistently high
188Re yields and low parent
breakthrough for periods of at least 2 months.
A HEDP (hydroxyethylidene-1,1-diphosphonic acid) vial
contained exactly 15 mg of Na2HEDP, 4.5 mg Sn2Cl-2H2O,
4.0 mg of gentisinic acid 98% and 0.1 mg NH4ReO4.A
second vial contained a sodium acetate trihydrate solution of
41 mg/ml in aqua distillate (0.3 M). After preparation the
HEDP kit was immediately stored at −20°C. To make
188Re-
HEDP, 1.0 ml NH4ReO4 solution (containing 0.01–0.1 mg
of NH4ReO4)a n d1m l
188ReO4− was added to the kit vial.
The whole mixture was heated for 20 min in a heating block
at 120°C and allowed to cool to room temperature for 10
min. Another 1 ml of 0.3 M sodium acetate trihydrate
solution was added to adjust the pH range to 5–6. The
radiochemical purity of
188Re-HEDP was determined by the
instant thin-layer chromatographic (ITLC) technique [7].
Treatment
Cohorts of three successive patients were treated with a
combination of capecitabine (Xeloda®; Roche, Woerden,
The Netherlands) and
188Re-HEDP. Capecitabine treatment
started 48 h before
188Re-HEDP administration. The first
cohort was treated with 1/3×2,500 mg/m
2 per day
capecitabine, followed by a weight-related dose of
37 MBq/kg body weight
188Re-HEDP. Capecitabine was
administered in twice daily doses for 14 days. Escalation of
administered doses of capecitabine were implemented in
increments of 1/3×2,500 mg/m
2 per day to a maximum
dose of 2,500 mg/m
2 per day capecitabine (the maximum
recommended dose for metastatic breast and colorectal
cancer). Follow-up lasted for 8 weeks with weekly blood
samples and 4-weekly history taken and physical exam.
Patients were hospitalized for 8 h after
188Re-HEDP
administration. Urine was collected during the 8 h follow-
ing injection of
188Re-HEDP. Whole-body images were
captured with a dual-head gamma camera at 6 h post-
injection (anterior and posterior; 10% energy window
around the peak of 155 keV, medium energy collimator,
scan speed 6 cm/min).
Analysis
If one dose limiting toxicity (DLT) would occur in the
cohort of three patients then the cohort would increase to
six patients. If a maximum of one of six patients would
have had a DLT then the next cohort would have been
tested. If at least two of six patients would have had a DLT
then the MTD (i.e. the dosage level of the previous cohort)
would have been reached. At least six patients were treated
in the final MTD group.
Any of the following events which were considered
possibly or probably related to the administration of
capecitabine,
188Re-HEDP or a combination of those were
considered a DLT during the 8 weeks of follow-up [using
National Cancer Institute (NCI) Common Terminology for
Adverse Events version 3.0]: grade 3–4 neutropaenic
infection (ANC < 1.0×10
9/l) with fever > 38.3°C; grade 4
neutropaenia lasting > 7 days; grade 4 thrombocytopaenia
(platelet count < 25×10
9/l); grade 3 thrombocytopaenia
lasting for > 7 days; any non-haematological grade 3 or 4
toxicity possibly related to study medication; grade 3–5
nausea, vomiting, mucositis, fatigue, tearing, nail distur-
bance, alopecia or diarrhoea; any life-threatening event
possibly related to the study drug. Disease progression was
not considered a DLT event.
Secondary end-points were the evaluation of pharmaco-
kinetics and biodistribution of
188Re-HEDP when com-
bined with capecitabine. Post-treatment scintigraphy was
compared with pre-treatment
99mTc-HDP scintigraphy
performed within 8 weeks of study entry. Regions of
interest (ROI analysis) were used to calculate lesion to
normal bone ratios (geometric mean corrected for soft
tissue uptake and background). The mean counts per pixel
calculated over three metastases were used as lesion value;
the mean counts per pixel for a ROI over the femur was
used as normal bone value. The same ROIs were used for
post- and pre-treatment scans in the same patient.
Urinary excretion of activity was measured during the
first 8 h after treatment and compared to literature values of
188Re-HEDP as monotherapy. Pooled urine samples were
collected from 0–4 h and 4–8 h following
188Re-HEDP
administration. The amount of activity in these samples was
determined by measurement of 15-ml, non-diluted samples
with a dose calibrator. For comparison with the adminis-
tered activity, the exact injected dose was determined by
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This procedure enabled determination of the amount of
activity excreted and, as a corollary, the relative amount of
activity retained within the body.
The extent of osteoblastic bone disease was determined
using the bone scan index as described by Blake et al. [21].
The skeleton was divided into four anatomical regions: (1)
spine and skull, (2) pelvis, (3) shoulder girdle and ribs and
(4) extremities. Each region was scored visually on a scale
of 0 to 10 for the apparent proportion of skeleton involved.
Scores for each region were summed, and the sum was
normalized to a scale of 0 to 100 as an index for the extent
of skeletal involvement.
Statistical methods
Descriptive statistics (n, mean, SD, minimum and maximum)
were calculated for quantitative variables; frequency counts
by category were determined for qualitative variables.
The bone scan index was correlated with the excreted
activity in urine using Pearson’s bivariate correlation
coefficient for continuous variables (R). The hypothesis ‘no
correlation’ versus the alternative hypothesis ‘significant
correlation’ was tested using Student’s t test (one-tailed).
Results
A total of 17 patients were enrolled in this study. Five
patients were excluded after screening because one patient
withdrew consent before the start of treatment (because of
too many visits to the hospital), three patients had
thrombocyte levels < 150×10
9/l and one patient had rapidly
progressive disease with a Karnofsky performance score <
60% before the start of treatment. All 12 treated patients
were included in the safety and toxicity analysis (the
primary end-point). All 12 treated patients were Caucasian
with a mean age of 70 years (range: 60–83) (Table 1).
Among the 12 patients who entered the treatment period,
11 patients completed both the treatment period and the
study course (9 weeks). One patient (patient 15) did not
complete the last visit because of progressive disease.
Adverse events (> grade 1 or > 1 patient) are listed in
Table 2. The first two cohorts were treated without
unacceptable adverse events. Five of six patients in the last
cohort were treated without unacceptable adverse events.
One patient (treated with 37 MBq/kg
188Re-HEDP and
2,500 mg/m
2 per day capecitabine) suffered from progres-
sive complaints of fatigue (grade 3), which made it
impossible to comply with the last follow-up visit.
Laboratory values showed a progressive increase of PSA
and alkaline phosphatase together with a prolonged and
unrecovered bone marrow suppression with anaemia (grade
3), thrombopaenia (grade 4) and leucopaenia/neutropaenia
(grade 2). He died of cancer-related events (progressive
bone marrow disease) 2 months after the end of the study.
Of six patients in the highest cohort he was the only patient
who suffered from a DLT. It was probably caused by
treatment-related toxicity aggravated by severe progression
of disease. The maximum tolerable dose of capecitabine in
combination with 37 MBq/kg
188Re-HEDP was therefore
2,500 mg/m
2 per day.
After onset of the study treatment, haematological
parameters were measured on a weekly basis (Fig. 1)a n d
serum chemistry on a monthly basis (Table 2). All patients
experienced an expected temporary decline in platelet count
in week 4 (mean ± 1 SD: −61.8±16.5%), 3 weeks after
188Re-HEDP administration, with subsequent recovery
(Fig. 1). Also as expected, there was a temporary decline
in white blood cell count in week 4 (mean ± 1 SD: −34.4±
17.8%), 3 weeks after
188Re-HEDP administration, with
recovery thereafter. The temporary increase in mean white
blood cell count in week 5 may be due to inter- and intra-
patient variations, typically seen in white blood cell count. It
was probably not related to the study treatment. Haemoglo-
bin levels were steady throughout the study course with a
mean change compared to baseline of −0.8±12.7% 4 weeks
after
188Re-HEDP administration and −5.8±11% at the end
of the study (Fig. 1).
Grades 1, 2, 3 and 4 haematological toxicity occurred in
6, 3, 0 and 1 of 12 patients, respectively. Creatinine levels
were stable throughout the study period for all patients.
Clinical adverse events included pain, fatigue, nausea,
vomiting, stomatitis and diarrhoea. Most adverse events
were probably related to capecitabine and were more
frequently encountered in cohorts 2 and 3 (Table 2). An
increase in pain happened in four patients, all more than
4 weeks after treatment with initially a good response.
These complaints were considered disease progression, not
related to study medication. One patient experienced the
hand-foot syndrome (grade 2) typically related to capecita-
bine. The hand-foot syndrome (palmar-plantar erythrody-
saesthesia or chemotherapy-induced acral erythema) is
characterized by numbness, dysaesthesia, tingling, swell-
ing, pain, erythema, desquamation, blistering and some-
times ulceration (not in this case). This patient proved not
to have a dihydropyrimidine dehydrogenase deficiency. He
fully recovered.
As mentioned above one serious adverse reaction was
observed (grade 4 thrombopaenia), probably related to
study treatment (patient 15). Other grade 3 toxicities were
probably related to disease progression (pain increase,
alkaline phosphatase increase) or other non-related causes
(exacerbation of cor pulmonale with pneumonia). The latter
patient was hospitalized. He was successfully treated with
antibiotics and diuretics. One of the four patients who
experienced an increase of bone pain was hospitalized for
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ous adverse events) were most probably not related to the
study treatment. No suspected unexpected serious adverse
reactions (SUSAR) occurred.
Secondary end-points included evaluation of urinary
excretion and uptake of
188Re-HEDP in pathological bone
lesions. Major protocol deviations leading to exclusion from
analysis of secondary end-points were found in two patients.
Table 1 Baseline findings and study treatment (
188Re-HEDP and capecitabine)
Patient Age TNM
a PSA
b KPS
c CTx
d RTx
e NTx
f 188Re-HEDP Capecitabine
2 70 T4NxMx 670 70% 6x Yes – 3359 MBq 800 mg 2dd
3 73 T4N0M+ 550 70% 10x Yes 2x 3163 MBq 1,000 mg 2dd
5 74 TxNxM+ 620 90% 6x ––2889 MBq 800 mg 2dd
6 65 T3N2M0 220 70% – Yes – 3744 MBq 1,800 mg 2dd
7 83 T3NxM0 800 60% –––2566 MBq 1,500 mg 2dd
8 69 T3NxM0 11 60% – Yes – 3472 MBq 1,800 mg 2dd
10 69 T4N+M+ 250 80% 10x – 4x 4040 MBq 2,800 mg 2dd
11 66 TxNxM+ 1500 60% 10x Yes – 3116 MBq 2,500 mg 2dd
14 74 T4NxM+ 510 80% –––3132 MBq 2,500 mg 2dd
15 61 T4NxM+ 440 90% –––3251 MBq 2,500 mg 2dd
16 60 T4N+M0 2200 70% –––2476 MBq 2,300 mg 2dd
17 76 T4N0Mx 360 60% – Yes – 3146 MBq 2,500 mg 2dd
aTNM stage at diagnosis
bPSA at screening/baseline in ng/ml
cKarnofsky performance score at screening/baseline
dCTx = docetaxel chemotherapy: 75 mg/m
2 every 3 weeks plus prednisone
eRTx = local radiotherapy received for pain palliation < 25% of the skeleton
fNTx = nuclear therapy: patient 3 received 2x
186Re-HEDP, patient 10 4x
153Sm-EDTMP
Patient Cohort 1 Cohort 2 Cohort 3
2356781 01 11 41 51 61 7
Alkaline phosphatase increase 4 2 3
Anaemia 1 2 3 1
AST/SGOT increase 1 1
Confusion 2 2
Cor pulmonale 3
Diarrhoea 2 1
Fatigue 2 2 3
Hand-foot syndrome 2
Hypo-albuminaemia 1 1 2
Hypo-phosphataemia 2
INR increase 2
Leucopaenia 1 2 1 1 2 2
Nausea 2 1 1 1
Neutropaenia 2 2
Pain increase 3 2 3 2
Pneumonia 3
Stomatitis 2
Thrombopaenia 1 1 1 1 1 1 1 1 4 2
Vomiting 1 1
Weight loss 21
Table 2 Adverse events, listed
per patient with grade of toxicity
given
a
aThis table includes adverse
events which are related or
unrelated to study drugs, with
either an intensity > grade 1
(according to NCI Common
Terminology Criteria for
Averse Events version 3.0) or
frequency > 1 patient
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patients. The mean urinary excretion of activity during the
first 8 h after injection was 45.7±11.9% (range: 24–60%).
As expected no focal activity was visualized outside the
skeleton, kidneys and bladder (Fig. 2). So the retained
activity was mostly retained in the skeleton. An expected
negative correlation was therefore found between urinary
excretion of activity and the extent of osteoblastic bone
disease (R=−0.83; p=0 . 0 0 1 ) .T h em e a nb o n es c a ni n d e xw a s
42.7±15.9% (range: 23–75%). Considering skeletal uptake
of activity: the lesion to normal bone ratio was 13.4±4.9 for
188Re-HEDP and 14.4±6.8 for
99mTc-HDP.
Efficacy will be further studied in a phase II study using
37 MBq/kg
188Re-HEDP in combination with 2,500 mg/m
2
per day. In the present phase I dose escalation study no
conclusions were drawn on efficacy.
Discussion
The haematological toxicity profile of
188Re-HEDP in
combination with capecitabine (up to 2,500 mg/m
2 per
day) is comparable to that of monotherapy with
188Re-
HEDP. An expected decline in platelet and white blood cell
count occurred 3–4 weeks after treatment with subsequent
recovery. Additive toxicity was attributed to capecitabine
use. One of six patients in the highest cohort experienced
unacceptable DLT. This patient had widespread metastatic
disease, but was in good clinical condition before treatment
(Karnofsky performance score 90%) and was not treated
with chemotherapy, nuclear therapy or radiotherapy before
study treatment. His PSA was 260 ng/ml with a doubling
time of 2 weeks before treatment. After treatment his PSA
and alkaline phosphatase further increased, reflecting
a
b
c
Fig. 1 Mean haematological
parameters (±1 standard
deviation) during the study
period of 9 weeks: haemoglobin
in mmol/l (a), platelet count ×
10
9/l (b) and white blood cell
count × 10
9/l (c)
1430 Eur J Nucl Med Mol Imaging (2009) 36:1425–1433progressive disease. He experienced grade 4 haematological
toxicity (thrombopaenia) and was not able to recover due to
progressive bone marrow disease.
188Re-HEDP is currently used to relieve pain in patients
with confirmed osteoblastic metastatic bone lesions that
enhance on
99mTc-HDP scintigraphy. Experience with
188Re-HEDP in pain reduction is somewhat limited, but
results have been quite promising. A number of publica-
tions show its efficacy [9–12]. Repeated treatment with
188Re-HEDP with an interval of 8 weeks enhanced pain
palliation and improved progression-free and overall sur-
vival [11]. Administered doses of around 37 MBq/kg
proved to be safe in several studies [10, 11, 22]. Expected
bone marrow depression occurred in most cases, but with
subsequent recovery. The severity of this depression is
related to the bone marrow reserve, which might be
compromised as a result of previous treatments or disease
progression [22]. Treatment regimens that combine
188Re-
HEDP with other modalities have never been tested. The
present study shows the safety of
188Re-HEDP combined
with capecitabine (up to 2,500 mg/m
2 per day).
Carrier-added
188Re-HEDP shows identical chemical
characteristics to
186Re-HEDP. The degree of skeletal
uptake of
188Re-HEDP correlated with the extent of
osteoblastic bone disease. The uptake of
188Re-HEDP in
skeletal lesions in the present study (mean ratio: 13.4±4.9)
is comparable to pre-treatment skeletal scintigraphy using
99mTc-HDP (mean ratio: 14.4±6.8). These findings corre-
late with pre-clinical data of
188Re-HEDP in rabbits [7].
However, because of differences in scanning parameters
(6 h versus 3 h p.i., energy peak, energy window, scanning
speed) a direct comparison has several limitations. The
present study was not designed for equivalence testing.
Nevertheless, it may be concluded that uptake of
188Re-
HEDP in skeletal lesions is sufficient when combined with
capecitabine. It is comparable to what may be expected
from pre-treatment scintigraphy using
99mTc-HDP.
Like
186Re-HEDP clearance of
188Re-HEDP is exclu-
sively renal, with the remainder of the dose retained in the
skeleton. The mean urinary excretion of activity during the
first 8 h after injection in the present study was 45.7±11.9%
(range: 24–60%). In another study
188Re-HEDP showed a
rapid urinary excretion within the first 8 h after therapy,
with approximately 41% of the
188Re-HEDP administered
being excreted [23]. This is comparable to our data. The
large range is attributed to large differences in the extent of
metastatic disease. It is unlikely that capecitabine has any
effect on urinary excretion or skeletal uptake of
188Re-
HEDP. The combination seems feasible.
Capecitabine is indicated as monotherapy in patients
with colorectal cancer and breast cancer. It is administered
as oral tablets in a dose of 1,250 mg/m
2 twice daily for
14 days and 1 week rest in cycles of 3 weeks [14]. Early in
vitro studies in human prostate cancer cell lines demon-
Fig. 2 Post-treatment scintigra-
phy 6 h after injection of
37 MBq/kg
188Re-HEDP
(anterior and posterior; 10%
energy window around the peak
of 155 keV, medium energy
collimator, scan speed
6 cm/min) (a) compared to pre-
treatment skeletal scintigraphy
3 h after injection of 600 MBq
99mTc-HDP (b)
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cells, necessary for the conversion to active 5-FU [19].
After administration of capecitabine a high anti-tumour
effect was found, with a 77% inhibition of growth [24]. The
beneficial effect of capecitabine in patients with hormone-
refractory prostate cancer was first reported in a patient
with advanced disease (multiple bone and liver metastases).
Capecitabine was given in a dose of 2,000 mg/m
2 per day
for 14 days of a 21-day cycle for 6 months. His PSA
normalized, the liver size decreased by 7 cm to a normal
size and the liver enzymes and alkaline phosphatase also
normalized [25]. This finding could not be confirmed in
phase II studies using capecitabine as a single agent in
hormone-refractory prostate cancer patients [26, 27]. It was
however concluded that combined treatment regimens
containing capecitabine should be considered, because
capecitabine appeared to modulate tumour biology [27].
The results of these early trials indicate that the role of
the 5-FU prodrug capecitabine alone or in combination is
yet unclear. Evidence is still low. However, prostate cancer
cells are sensitive to radiotherapy (both external beam
radiotherapy and systemic radionuclide therapy) and poten-
tially to capecitabine [24]. The proven effects of capecita-
bine as a radiation sensitizer in other cancer types, the lack
of data on capecitabine as a radiation sensitizer in advanced
prostate cancer and the convenience and toxicity profile of
capecitabine make it a good candidate for phase I/II testing
in hormone-refractory prostate cancer patients in combina-
tion with
188Re-HEDP.
Another agent that may be used in combination with
188Re-HEDP is docetaxel. In contrast to capecitabine, it is
not commonly used as a radiation sensitizer and it has some
disadvantages in comparison with capecitabine (i.e. intra-
venous infusion, costly, more side effects). In the present
study capecitabine was therefore tested instead of doce-
taxel. As an anti-tumour agent docetaxel is however more
effective in hormone-refractory prostate cancer and it may
be used as a radiation sensitizer nevertheless [28]. More-
over, docetaxel and capecitabine may be combined with
188Re-HEDP together. Taxanes were found to upregulate
the tumoural activity of thymidine phosphorylase (a critical
enzyme for capecitabine activation) and have shown
synergistic cytotoxic activity when combined with capeci-
tabine [29, 30]. Docetaxel in combination with capecitabine
has already been tested in clinical phase I/II studies with
promising results [31, 32]. The docetaxel/capecitabine
combination proved to be tolerable and effective. Random-
ized trials have so far not been conducted.
Capecitabine in combination with
188Re-HEDP proved
to be feasible and safe. The next step in the enhancement of
efficacy may be docetaxel, capecitabine and
188Re-HEDP
as triple therapy in hormone-refractory prostate cancer
patients with multiple osseous metastases.
Conclusion
The maximum tolerable dose of capecitabine in combina-
tion with 37 MBq/kg
188Re-HEDP is 2,500 mg/m
2 per day.
The combination is feasible and safe. Efficacy, using the
maximum dose, will be tested in a phase II trial.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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